Robert W. Baird analyst Colin Sebastian maintained a Buy rating on Paypal Holdings (PYPL – Research Report) yesterday and set a price target of $175.00. The company’s shares closed last Friday at $116.67, close to its 52-week low of $92.25.
According to TipRanks.com, Sebastian is a 5-star analyst with an average return of 17.2% and a 56.6% success rate. Sebastian covers the Technology sector, focusing on stocks such as Alphabet Class A, Alphabet Class C, and Playtika Holding.
Paypal Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $180.63, which is a 55.7% upside from current levels. In a report issued on March 30, Goldman Sachs also initiated coverage with a Buy rating on the stock with a $144.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on Paypal Holdings’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $6.92 billion and net profit of $801 million. In comparison, last year the company earned revenue of $12.2 billion and had a net profit of $1.57 billion.
Based on the recent corporate insider activity of 77 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PYPL in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PayPal Holdings, Inc. is a digital payments platform that enables its customers to send and receive payments. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, iZettle and Hyperwallet products. The company was founded in December 1998 and is headquartered in San Jose, CA.
Read More on PYPL:
- Leerink Partners Thinks Aptinyx’s Stock is Going to Recover
- Leerink Partners Thinks Connect Biopharma Holdings’ Stock is Going to Recover
- Leerink Partners Thinks Mereo Biopharma Group Plc’s Stock is Going to Recover
- Assembly Biosciences (ASMB) Receives a Buy from Robert W. Baird
- Ionis Pharmaceuticals (IONS) Initiated with a Hold at Leerink Partners
